For patients with KRAS G12C mutated NSCLC, how would you decide between using targeted therapy with sotorasib vs adagrasib?

Sotorasib is currently my drug of choice for now, since it is FDA approved. The KRYSTAL-1 results for adagrasib were presented at ASCO 2022, and the efficacy is very similar vs sotorasib, 43% vs 37% ORR, 80% DCR for both, 6.5 vs 6.8 mo mPFS, and 12.6 vs 12.5 mo mOS. Adagrasib does seem to have more ...

The incidence of CNS metastases in KRAS^G12Cmutated NSCLC is approximately 27 to 42% at diagnosis and is associated with a poor prognosis. The current standard of care for this group of patients is docetaxel plus ramucirumab which is associated with a median PFS of approximately 3 to 5 months. (Furuy...